Menu

Image of the Day: Tumor Organoids

Miniature versions of bladder cancers could help physicians identify personalized treatment options for patients.

Apr 11, 2018
The Scientist Staff, The Scientist Staff

Organoids created from the bladder cancers of patients mimic the characteristics of each person’s tumor and may be used for screening interventions.COLUMBIA UNIVERSITY IRVING MEDICAL CENTER

Organoids—miniature versions of organs grown in vitro from tissue-specific progenitor cells—were first produced in 2013. Last week (April 5), researchers reported in Cell that they created organoids from human bladder cancer tumors for the first time. The organoids are unique to each patient’s tumor and could offer a novel approach to studying the molecular mechanisms associated with resistance to cancer-fighting drugs.

“The great advantage of organoids is that they are essentially avatars of a patient's tumor,” study coauthor Michael Shen, a geneticist at Columbia University, says in a press release. “Having these personalized laboratory models, which we can make in a matter of weeks, will let us test multiple different drugs on the tumor and help us bring precision medicine to individuals with bladder cancer.”

See “My Mighty Mouse

S.H. Lee et al., “Tumor evolution and drug response in patient-derived organoid models of bladder cancer,” Cell, doi:10.1016/j.cell.2018.03.017, 2018.

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.